Here is the legislative truth nobody at the National Conference of State Legislatures wants to say out loud: the medical / adult-use distinction in state cannabis law is, at this point, mostly theater. The same product, made by the same operators, in the same facilities, sold by the same employees, to the same adult customers — gets a different state-law label depending on whether the customer checked “patient” or “consumer” at the door. In adult-use states, the label has been “consumer.” In medical-only states, the label has been “patient.” The plant is the same.
For thirty years the distinction barely mattered for federal purposes because federal law treated all marijuana as Schedule I regardless. April 22, 2026 ended that. DOJ now treats marijuana subject to a state medical marijuana license as Schedule III, while leaving everything else in Schedule I. The label suddenly does eight different jobs at once: federal scheduling, 280E, banking risk, payment-network feasibility, DEA registration eligibility, investor disclosure, M&A premium, and tax normalization. States that haven’t built a state medical marijuana licensing system are leaving every one of those federal recognitions on the table.
The fix is the OTC Therapeutic Cannabis Endorsement model. Universal medical endorsement on every cannabis license. Adult self-certification 21+. Transaction-level medical-purpose records. Certified consultant or pharmacist overlay. Enhanced traditional patient tier preserved. Public-health and anti-diversion controls strengthened. This post is the legislative architecture, ten pillars, with model statutory language. State lawmakers can have it tomorrow.
Why the OTC Therapeutic Cannabis Endorsement is the right state-law response
Three reasons.
First, the channel-based architecture. DOJ’s Final Order is not a general-legalization order. It moved a slice of marijuana — FDA-approved products and state-medical-licensed activity — into Schedule III. The state-policy implication is obvious: bring as much licensed cannabis activity as possible inside the medical channel, or accept that your operators are excluded from federal recognition.
Second, the legislative path of least resistance. The OTC model does not require eliminating adult-use access politically. It does not require narrow qualifying conditions or physician gatekeeping. It does not require flipping recreational consumers into traditional patients. It requires layering medical endorsement, self-certification, and recordkeeping on top of existing licensure.
Third, federal defensibility. D.C. has used adult self-certification since 2022. Washington has used medical retail endorsement and certified consultants for over a decade. Combining those proven concepts produces an OTC therapeutic access framework that DOJ, Treasury, FinCEN, banks, and card networks can underwrite. We are not inventing legal fiction — we are combining tested state programs into one coherent statute.
The 10 Pillars of the OTC Therapeutic Cannabis Endorsement Model
Pillar 1 — Universal medical cannabis endorsement on every license
Every cultivation, processing, manufacturing, testing, transport, distribution, delivery, and retail license either automatically becomes, or is required to obtain, a state medical cannabis endorsement. The endorsement is not just permission to sell to registered patients. It defines the licensed activity as medical, therapeutic, wellness, symptom-management, harm-reduction, or palliative under state law.
Model statutory language:
A cannabis license issued under this Act is a state medical cannabis license when the licensee holds a medical cannabis endorsement. Cannabis cultivated, manufactured, processed, transported, tested, distributed, dispensed, delivered, or sold under a medical cannabis endorsement is authorized for medical, therapeutic, wellness, symptom-management, harm-reduction, or palliative purposes under the laws of this State.
This is the heart of the model. It moves the question from “adult-use or medical?” to “licensed medical-endorsed or unlicensed?” — which is the question federal agencies, banks, and payment processors can underwrite.
Pillar 2 — Adult self-certification for OTC therapeutic access
Adults 21 and older may self-certify that cannabis is being purchased for a medical, therapeutic, wellness, symptom-management, or harm-reduction purpose. The certification can include categories: pain, sleep, anxiety, stress, appetite, nausea, recovery, inflammation, PTSD symptoms, opioid reduction, alcohol reduction, or other wellness purposes.
D.C. already permits adults 21+ to self-certify medical use as part of patient registration. The OTC model layers self-certification onto every adult sale, not just registration.
Model statutory language:
An adult 21 years of age or older may qualify for OTC therapeutic cannabis access by completing a self-certification, in a form prescribed by the Department, stating that the adult is obtaining cannabis for medical, therapeutic, wellness, symptom-management, harm-reduction, or palliative purposes.
See Adult Self-Certification for Cannabis for the operator implementation playbook.
Pillar 3 — Retain enhanced traditional patient protections
Do not flatten serious patients into the general consumer bucket. Maintain the traditional registered patient program as an enhanced tier. Registered patients keep:
- Higher possession limits
- Tax preferences
- Home-grow rights (where applicable)
- Caregiver authorization
- Employment / housing protections (where politically feasible)
- Priority access
- Delivery rights
- Stronger privacy protections
The OTC model expands access; it should not weaken patient access.
Pillar 4 — Certified medical cannabis consultant or pharmacist / practitioner overlay
Each medically endorsed retailer maintains a certified medical cannabis consultant, pharmacist, nurse, physician assistant, physician, or trained therapeutic cannabis specialist on site or available via telehealth during business hours. Washington’s consultant program is the proof of concept.
Required consultant review for: first-time users, high-potency products, high-quantity transactions, registered patients with complex needs, seniors, drug-interaction risk disclosures, adverse-event follow-up.
See Medical Cannabis Consultant & Pharmacist Overlay for the program design.
Pillar 5 — Transaction-level medical records
Every sale under the endorsement generates a record:
- License number
- Purchaser age verification
- Self-certification ID or patient card
- Product SKU
- Cannabinoid profile
- Dosage / serving information
- Quantity
- Intended-use category
- Transaction date / time
- Employee or consultant ID
- Required warnings or consult flags
Available to state regulators, summarized for federal-readiness certificates, protected from unnecessary disclosure.
This is the most important operational control. Banks, IRS, DEA, and card networks do not need slogans — they need auditable records showing the transaction was within the state medical cannabis program.
Pillar 6 — Product classification, labeling, and potency controls
Classify products by:
- Dosage form
- Potency tier
- Route of administration
- Cannabinoid profile
- Intoxicating potential
- Intended-use category
Higher-risk products get additional labeling and mandatory consultation. Labels must avoid unauthorized FDCA disease-treatment claims unless supported and permitted. The state can record consumer use purpose without letting the product label claim to treat, cure, or prevent disease.
Pillar 7 — DEA registration readiness
Each licensee maintains a federal-readiness file: license + endorsement, owners and control persons, premises, security plan, seed-to-sale records, disposal SOP, diversion-control plan, inventory, adverse-event log, state inspection history, tax compliance, banking compliance, product testing, transaction medical-purpose records.
If DEA opens or requires registration under the Final Order, operators with this file move quickly and credibly. See Federal Cannabis License: 10 Critical DEA Steps.
Pillar 8 — Bank-ready and card-ready compliance certificates
The state regulator issues regulator-verifiable compliance certificates for endorsed licensees:
- License status
- Medical endorsement status
- Good standing
- Inspection history
- Disciplinary status
- Tax compliance status
- Ownership verification
- OTC therapeutic access program participation
Plus a regulator API or secure verification portal for banks and payment processors. FinCEN guidance already requires banks to verify state license status; the state should make verification easy.
Pillar 9 — Activity and revenue segmentation
Until federal guidance becomes stable, licensees must segment activities and revenue by category:
- Traditional registered patient sales
- OTC self-certified therapeutic sales
- Adult-use legacy sales (if any remain)
- Hemp-derived products
- Accessories
- Non-cannabis sales
Shared expenses allocated through documented methodology. This protects tax positions and supports IRS apportionment. See 280E Retrospective Relief for tax-side mechanics.
Pillar 10 — Public-health and anti-diversion controls
- No sales to minors except through caregiver / patient rules
- No interstate shipments
- No unlicensed products
- Strict testing
- Recall authority
- Advertising limits
- Product warnings
- Safe-storage education
- Adverse-event reporting
- Limits for high-potency products
- Suspicious activity reporting
- Enforcement against diversion
The more adult-use the system looks, the more these controls matter.
Model statutory architecture (10 articles)
The model bill, at a glance:
Article
Purpose
1 — Purpose & Findings
State interest in bringing licensed cannabis activity inside a regulated medical-access framework
2 — Definitions
OTC therapeutic cannabis, medical cannabis endorsement, adult self-certification, therapeutic-use category, qualified adult participant, traditional registered patient, certified cannabis consultant, medical-endorsed licensee, federal-readiness file
3 — Universal Medical Endorsement
Pillar 1
4 — Adult Self-Certification
Pillar 2
5 — Traditional Patient Tier
Pillar 3
6 — Consultant / Pharmacist Overlay
Pillar 4
7 — Transaction Records & Privacy
Pillar 5
8 — Bank & Federal Compliance Certificates
Pillar 8
9 — Federal Recognition Clause
“Cannabis and cannabis products handled under a medical cannabis endorsement are deemed by this State to be marijuana subject to a state medical marijuana license for all purposes, including federal recognition to the fullest extent permitted by federal law.”
10 — Severability & No-Overclaim
“Nothing in this Act requires any person to violate federal law; the State is structuring licensed activity to maximize federal recognition and compliance, not purporting to bind federal agencies.”
Severability matters because litigation is coming. The Final Order itself is litigation bait. The model statute should survive partial invalidation.
Implementation timeline for state lawmakers
First 30 days
- Draft state-specific bill from the model
- Issue regulator emergency rules for transition
- Design adult self-certification form and privacy architecture
- Design bank/regulator verification certificate
- Map existing license classes to medical-endorsed equivalents
First 90 days
- Begin endorsement applications for existing licensees
- Train and certify cannabis consultants or therapeutic-use specialists
- Launch transaction-record fields in POS / seed-to-sale systems
- Issue guidance to operators, CPAs, banks, and payment processors
- Create template federal-readiness files
First 180 days
- Mandate medical endorsement for all licensed cannabis sales
- Issue first compliance certificates
- Publish banking due diligence portal
- Adopt allocation and revenue segmentation rules
Litigation and political risks
“Sham medical” challenge
Opponents will argue self-certification turns medical cannabis into adult-use with paperwork. The defense: OTC products routinely use self-selection; D.C. and Washington have proven the concept; the model imposes real controls (training, consultants, records, traditional patient protections).
Federal nonrecognition
DEA, IRS, FinCEN, or a court could conclude some endorsed activity isn’t enough. The defense: don’t overclaim; assert federal recognition “to the fullest extent permitted by federal law.”
FDCA drug claims
Product labels can’t make unapproved disease-treatment claims merely because the transaction is medical-purpose. The state distinguishes consumer/patient self-certification from product claims.
Banking still requires BSA compliance
The model improves but does not eliminate compliance obligations. State regulators must cooperate with banks.
Card networks may lag
Networks may wait for FinCEN updates before accepting medical cannabis transactions. Build the card-ready file now.
See State-by-State Schedule III Conversion Playbook for state-type-specific implementation guidance.
OTC Therapeutic Cannabis Endorsement FAQ
Does the OTC Endorsement model legalize cannabis federally?
No. State law cannot override federal law. The model maximizes federal recognition for state-licensed activity but does not bind DEA, IRS, or any federal agency.
How does this differ from existing state medical programs?
Existing medical programs typically require physician recommendations and narrow qualifying conditions. The OTC model uses adult self-certification 21+ for therapeutic-use categories without physician gatekeeping. Traditional patient programs are preserved as enhanced tiers within the broader OTC framework.
What states can adopt this?
All 50 — adult-use states, medical-only states, low-THC states, and prohibition states. Each gets a different implementation path. See the state-by-state playbook.
What about the FDCA / FDA?
FDA still regulates drug claims, dosage forms, and approved products. The model expressly avoids unauthorized drug claims and preserves FDA jurisdiction over labeling.
Can a state pass this without amending its constitution?
Generally yes. Most state cannabis statutes can be amended through ordinary legislative process. State constitutional amendments may be required only where adult-use was passed by ballot with constitutional language.
What does Howard East charge for the State Model Act package?
Custom by state. Typically includes: legislative drafting, policy memo, fiscal/tax impact analysis, federal-defensibility analysis, and committee testimony. Engagement varies from $50K to $250K depending on scope. Contact us for state-specific scoping.
Get the State OTC Therapeutic Cannabis Model Act package
If you are a governor’s policy director, state attorney general, state senator, state representative, cannabis committee staff, or AG-office cannabis policy lead — the State OTC Therapeutic Cannabis Model Act package is built for you. We deliver the legislative draft, the policy memo, the fiscal/tax impact analysis, the federal-defensibility brief, and committee testimony.
The states that pass first give their operators a federal-recognition advantage that translates immediately into tax, banking, payments, and valuation upside. The states that wait are explaining to constituents in 2027 why every operator from a neighboring state is sitting on a 30% enterprise value premium.
Get the State Model Act package.
For the full hub: Schedule III Cannabis: The Operator, Lawyer & Investor Hub.
- Adult Self-Certification for Cannabis (Cluster 6)
- Medical Cannabis Consultant / Pharmacist Overlay (Cluster 10)
- State-by-State Schedule III Conversion Playbook (Cluster 8)
- Howard East corporate law — for entity-formation work supporting state legislative engagement
- DOJ Final Order
- Executive Order 14370 — Increasing Medical Marijuana and CBD Research
- Article + LegalService + FAQPage
External ≥2
Cross-site ≥1
Schedule III Cannabis · Federal Cannabis Legalization · Cannabis Laws
OTC therapeutic cannabis · cannabis Model Act · state medical cannabis endorsement · therapeutic cannabis legislation · adult self-certification · medical cannabis endorsement · Schedule III · state cannabis reform · D.C. self-certification · Washington medical cannabis consultant
Want the full Schedule III playbook?
This post is one cluster of The Schedule III Cannabis Hub, the operator, lawyer, and investor briefing on DOJ’s April 2026 Final Order.
